Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 6 of 44, showing 5 Applications out of 217 total, starting on record 26, ending on 30

# Protocol No Study Title Investigator(s) & Site(s) Application Status

26.

ECCT/19/04/03   Phase III pediatric study with the L-PZQ ODTs
    An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®)   
Principal Investigator(s)
1. Maurice Reuben Odiere
Site(s) in Kenya
KEMRI-Centre for Global Health Research (CGHR)
 
Trial Status Suspended
Protocol Date 20-02-2019
View

27.

ECCT/19/03/04   NIFTY
      Non-Inferiority Fractional-Doses Trial For Yellow Fever Vaccine         
Principal Investigator(s)
1. George Warimwe
Site(s) in Kenya
KEMRI Kilifi
 
Trial Status Suspended
Protocol Date 04-03-2019
View

28.

ECCT/19/03/03   Biofire FilmArray Gobal Fever GF Panel
    Clinical Evaluation of the FilmArray Gobal Fever GF Panel   
Principal Investigator(s)
1. JOHN WAITUMBI
Site(s) in Kenya
KEMRI Walter Reed Project USAMRD A/K Kisumu
 
Trial Status (not set!)
Protocol Date 21-02-2018
View

29.

ECCT/19/04/01   A study to determine if a new shigella vaccine (Shigella4V) is safe, induces immunity and the best dose among Kenyan infants.
    Safety and immunogenicity of a Shigella-tetravalent bioconjugate vaccine: A phase 1/2 randomized controlled and age descending study including dose finding in 9-month-old infants   
Principal Investigator(s)
1. Mainga Hamaluba
2. Kosgei Josphat
Site(s) in Kenya
1. KEMRI-United States Army Medical Research Unit-Kenya, Kericho (Kericho county)
2. KEMRI Wellcome Trust Research Program-CGMR-C (Kilifi county)
 
Trial Status Suspended
Protocol Date 09-07-2019
View

30.

ECCT/19/03/02   PREVENT TD
    A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD)   
Principal Investigator(s)
1. Flynn Alexander
Site(s) in Kenya
Nyati Barracks, British Army Training Unit, Kenya
 
Trial Status Stopped
Protocol Date 14-11-2016
View